Prurigo nodularis is a chronic inflammatory skin disorder marked by intensely itchy nodules, significantly impacting patients' quality of life. It accounts for approximately 0.19% prevalence in the United States. The growing focus on prurigo nodularis therapeutics is driven by unmet clinical needs, rising awareness, and increasing research investments. Several prurigo nodularis drug candidates are currently in clinical trials, with promising biologics targeting the IL-31 and IL-4/IL-13 pathways. The prurigo nodularis pipeline analysis by the publisher highlights strong market potential, fueled by advancements in dermatological treatments and the development of targeted therapies expected to boost market growth in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to prurigo nodularis.
Prurigo nodularis treatment involves corticosteroids, antihistamines, immunomodulators, and emerging biologic therapies to reduce itch, inflammation, and nodule formation while improving patients’ quality of life. For instance, in August 2024, Galderma’s Nemluvio (nemolizumab) received U.S. FDA approval as the first monoclonal antibody targeting IL-31 signaling for prurigo nodularis, following positive phase III OLYMPIA trial results demonstrating rapid itch and lesion improvement.
Interleukin inhibitors are gaining prominence in the prurigo nodularis pipeline. For example, nemolizumab, an interleukin-31 receptor alpha antagonist, is in a phase 3 trial. It has shown significant improvement in itch reduction and lesion healing by targeting the neuroimmune pathway. This class of drugs offers a promising approach for treating moderate-to-severe prurigo nodularis.
This product will be delivered within 3-5 business days.
Report Coverage
The Prurigo Nodularis Pipeline Analysis Report by the publisher gives comprehensive insights into prurigo nodularis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for prurigo nodularis. The prurigo nodularis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The prurigo nodularis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with prurigo nodularis treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to prurigo nodularis.
Prurigo Nodularis Pipeline Outlook
Prurigo nodularis is a chronic inflammatory skin condition marked by intensely itchy nodules that often develop due to repeated scratching. It is associated with neuroimmune dysregulation, leading to skin thickening and scarring. The disease typically occurs in adults and is often linked to underlying conditions such as atopic dermatitis, liver or kidney disease, or psychological stress.Prurigo nodularis treatment involves corticosteroids, antihistamines, immunomodulators, and emerging biologic therapies to reduce itch, inflammation, and nodule formation while improving patients’ quality of life. For instance, in August 2024, Galderma’s Nemluvio (nemolizumab) received U.S. FDA approval as the first monoclonal antibody targeting IL-31 signaling for prurigo nodularis, following positive phase III OLYMPIA trial results demonstrating rapid itch and lesion improvement.
Prurigo Nodularis Epidemiology
According to studies, the global annual prevalence of prurigo nodularis ranges from 6.52 to 72 per 100,100 people. In the United States, the estimated prevalence is approximately 0.19%. In the United Kingdom, about 18,000 individuals are affected, while in Japan, the disease impacts an estimated 5.5 million adults. Patients often face a high disease burden with increased risks of psychiatric disorders and systemic illnesses.Prurigo Nodularis - Pipeline Therapeutic Assessment
This section of the report covers the analysis of prurigo nodularis drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal Antibodies
- Small Molecules
- Biologics
- Topical Agents
- Peptides
By Route of Administration
- Oral
- Parenteral
- Others
Prurigo Nodularis Pipeline Assessment Segmentation by Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III holds the largest share at 68.75% of the total prurigo nodularis clinical trials, indicating robust clinical advancement in prurigo nodularis drug development. Phase IV follows with 6.25%, while Phase I and Phase II each account for 12.5%.Prurigo Nodularis Pipeline Assessment Segmentation by Drug Classes
The drug molecule categories covered under the prurigo nodularis pipeline analysis include monoclonal antibodies, small molecules, biologics, topical agents, and peptides. The prurigo nodularis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for prurigo nodularis.Interleukin inhibitors are gaining prominence in the prurigo nodularis pipeline. For example, nemolizumab, an interleukin-31 receptor alpha antagonist, is in a phase 3 trial. It has shown significant improvement in itch reduction and lesion healing by targeting the neuroimmune pathway. This class of drugs offers a promising approach for treating moderate-to-severe prurigo nodularis.
Prurigo Nodularis Clinical Trials - Key Players
The report for the prurigo nodularis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed prurigo nodularis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in prurigo nodularis clinical trials:- Amgen
- Incyte Corporation
- Celldex Therapeutics
- Keymed Biosciences Co.Ltd.
- Hengrui Pharmaceutical Co., Ltd.
- Galderma R&D
- Sanofi
- Regeneron Pharmaceuticals
- AbbVie
- Trevi Therapeutics
- Vyne Therapeutics Inc.
Prurigo Nodularis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for prurigo nodularis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of prurigo nodularis drug candidates.Drug: Povorcitinib
Povorcitinib is currently being evaluated by Incyte Corporation in a Phase III trial (STOP-PN2) for prurigo nodularis (PN). Povorcitinib is an oral JAK1 inhibitor, showing promise in treating inflammatory skin diseases, including hidradenitis suppurativa and vitiligo. This randomized, double-blind, placebo-controlled study aims to assess the drug’s efficacy in reducing itch and skin lesions.Drug: SHR-1819 Injection
SHR-1819 is a novel monoclonal antibody developed by Guangdong Hengrui Pharmaceutical Co., Ltd, currently undergoing a Phase II/III trial to assess its efficacy and safety in adult patients with prurigo nodularis. The study is evaluating SHR-1819's ability to block hIL-4Ra, a key target in type 2 inflammatory pathways, aiming to reduce chronic itch and nodular lesions.Drug: Ruxolitinib Cream
Ruxolitinib cream (Opzelura) is currently being evaluated in a Phase I study sponsored by Incyte Corporation to determine its safety and tolerability under maximal use conditions in adults with prurigo nodularis (PN). This selective JAK1/JAK2 inhibitor, already FDA-approved for vitiligo and atopic dermatitis, is being studied for its potential to address PN’s inflammatory skin lesions.Reasons To Buy This Report
The Prurigo Nodularis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for prurigo nodularis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within prurigo nodularis pipeline insights.Key Questions Answered in the Prurigo Nodularis Pipeline Insight Report
- Which companies/institutions are leading the prurigo nodularis drug development?
- What is the efficacy and safety profile of prurigo nodularis pipeline drugs?
- Which company is leading the prurigo nodularis pipeline development activities?
- What is the current prurigo nodularis commercial assessment?
- What are the opportunities and challenges present in the prurigo nodularis pipeline landscape?
- What is the efficacy and safety profile of prurigo nodularis pipeline drugs?
- Which company is conducting major trials for prurigo nodularis drugs?
- Which companies/institutions are involved in prurigo nodularis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in prurigo nodularis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Prurigo Nodularis
4 Patient Profile: Prurigo Nodularis
5 Prurigo Nodularis: Epidemiology Snapshot
6 Prurigo Nodularis: Market Dynamics
7 Prurigo Nodularis: Key Facts Covered
8 Prurigo Nodularis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Prurigo Nodularis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Prurigo Nodularis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Prurigo Nodularis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Prurigo Nodularis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Prurigo Nodularis, Key Drug Pipeline Companies
